[2019 novel coronavirus, angiotensin converting enzyme 2 and cardiovascular drugs].
作者信息
Shi H Z, Ma P, Gao F Y, Chen G L, Wang Y H, Xian X D, Dong E D
机构信息
Institute of Cardiovascular Sciences, Peking University Health Science Center, Beijing 100191, China.
Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides of National Health Commision, Key Laboratory of Molecular Cardiovascular Science of Ministry of Education, Beijing Key Laboratory of Cardiovascular Receptors Research, Beijing 100191, China.
出版信息
Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Jul 24;48(7):532-538. doi: 10.3760/cma.j.cn112148-20200308-00171.
Abstract
摘要
相似文献
1
[2019 novel coronavirus, angiotensin converting enzyme 2 and cardiovascular drugs].[2019新型冠状病毒、血管紧张素转换酶2与心血管药物]
Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Jul 24;48(7):532-538. doi: 10.3760/cma.j.cn112148-20200308-00171.
2
[Angiotension converting enzyme 2 in the context of 2019 novel coronavirus infection：friend or foe？].2019新型冠状病毒感染中的血管紧张素转换酶2：朋友还是敌人？
Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Jul 24;48(7):527-531. doi: 10.3760/cma.j.cn112148-20200303-00149.
3
Cardiovascular disease and the impact of COVID-19.心血管疾病与2019冠状病毒病的影响
J Card Surg. 2020 Aug;35(8):2113. doi: 10.1111/jocs.14682. Epub 2020 Jun 16.
4
COVID-19 and the cardiovascular system.新型冠状病毒肺炎与心血管系统。
Nat Rev Cardiol. 2020 May;17(5):259-260. doi: 10.1038/s41569-020-0360-5.
5
COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure.心力衰竭背景下COVID-19对肾素-血管紧张素系统的干扰
mBio. 2020 May 22;11(3):e00946-20. doi: 10.1128/mBio.00946-20.
6
COVID-19: The heart of the issue.新冠病毒：问题的核心。
J Card Surg. 2020 Aug;35(8):2112. doi: 10.1111/jocs.14684. Epub 2020 Jun 16.
7
Central involvement of SARS-CoV-2 may aggravate ARDS and hypertension.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的中枢神经系统受累可能会加重急性呼吸窘迫综合征（ARDS）和高血压。
J Renin Angiotensin Aldosterone Syst. 2020 Oct-Dec;21(4):1470320320972015. doi: 10.1177/1470320320972015.
8
Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体阻滞剂对无高血压的新冠患者有益吗？
Pharmacol Res. 2020 Sep;159:104959. doi: 10.1016/j.phrs.2020.104959. Epub 2020 Jun 4.
9
[Angiotensin-converting enzyme 2 and coronavirus: research update on pathogenesis of the infection induced by this indissoluble bond].[血管紧张素转换酶2与冠状病毒：关于这种不解之缘引发感染的发病机制的研究进展]
Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Jul 24;48(7):539-545. doi: 10.3760/cma.j.cn112148-20200224-00121.
10
Is low sodium intake a risk factor for severe and fatal COVID-19 infection?低钠摄入是严重和致命的COVID-19感染的危险因素吗？
Eur J Intern Med. 2020 May;75:109. doi: 10.1016/j.ejim.2020.04.003. Epub 2020 Apr 8.
引用本文的文献
1
Scientific statement of the Chinese Society of Cardiology (CSC) on using of renin angiotensin system blockers in patients with cardiovascular disease and COVID-19.中国心脏学会（CSC）关于在心血管疾病合并新型冠状病毒肺炎（COVID-19）患者中使用肾素血管紧张素系统阻滞剂的科学声明。
J Geriatr Cardiol. 2020 May;17(5):241-242. doi: 10.11909/j.issn.1671-5411.2020.05.001.
Zotero 插件